Combination lurbinectedin and doxorubicin versus physician »s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
Nom du journal : Lancet Respir Med
Année : 2023
Volume : 11
Page de départ : 74-86
